Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019;6(1):34-41.
doi: 10.14283/jpad.2018.41.

Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study

V Pérez-Grijalba  1 , J Romero, P Pesini, L Sarasa, I Monleón, I San-José, J Arbizu, P Martínez-Lage, J Munuera, A Ruiz, L Tárraga, M Boada, M Sarasa
Affiliations
Multicenter Study

Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study

V Pérez-Grijalba et al. J Prev Alzheimers Dis. 2019.

Abstract

Background: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies.

Objectives: This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years.

Design: Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern.

Results: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF).

Conclusions: TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.

Keywords: Alzheimer’s disease; Aβ ratio; biomarker; plasma; β-amyloid (Aβ).

PubMed Disclaimer

Conflict of interest statement

VPG, PP, JR, ISJ, LS, IM and MS are employees of Araclon Biotech. All other co-authors do not have conflicts of interest related to this study.

Figures

Figure 1
Figure 1
TP42/40 levels in the different groups of the study population and TP42/40 utility in detecting progression to AD
Figure 2
Figure 2
Correlation of plasma TP42/40 with cortical Aβ deposition and CSF biomarkers at baseline
See this image and copyright information in PMC

References

    1. Lacosta AM, Insua D, Badi H, Pesini P, Sarasa M. Neurofibrillary Tangles of Abetax–40 in Alzheimer's Disease Brains. J Alzheimers Dis. 2017;58:661–667. 10.3233/JAD-170163 PubMed PMID: 28453491. - DOI - PubMed
    1. Brookmeyer R, Johnson E, Ziegler–Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–191. 10.1016/j.jalz.2007.04.381 PubMed PMID: 19595937. - DOI - PubMed
    1. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild–to–moderate Alzheimer's disease. N Engl J Med. 2014;370:311–321. 10.1056/NEJMoa1312889 PubMed PMID: 24450890. - DOI - PubMed
    1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild–to–moderate Alzheimer's disease. N Engl J Med. 2014;370:322–333. 10.1056/NEJMoa1304839 PubMed PMID: 24450891, PMCID 4159618. - DOI - PMC - PubMed
    1. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 - PMC - PubMed

Publication types

MeSH terms